证券代码：603858 证券简称：步长制药 公告编号：2023-145 山东步长制药股份有限公司 第四届董事会第四十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第四届董事会第四十四次 会议的通知于 2023 年 9 月 1 日发出，会议于 2023 年 9 月 6 日 13 时以通讯方式 召开，应参会董事 15 人，实参会董事 15 人，会议由董事长赵涛先生主持。会议 出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及《山 东步长制药股份有限公司章程》的相关规定，合法有效。 经与会董事研究，会议审议通过了如下议案： 1、《关于公司拟转让控股子公司股权暨放弃优先受让权的议案》 因业务发展需要，公司拟以 0 元人民币将所持有的步长健康产业（浙江）有 限公司（以下简称"步长健康（浙江）"）8.5%股权转让给海口鑫营氧投资合伙企 业（有限合伙）（以下简称"海口鑫营氧"）。胡存超拟将步长健康（浙江）1%股 权转让给海口鑫营氧；李辉拟将步长健康（浙江）0.5 ...

证券代码：603858 证券简称：步长制药 公告编号：2023-143 山东步长制药股份有限公司 关于控股子公司获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）控股子公司四川泸州步长生 物制药有限公司在研品种"注射用 BC001"新增适应症的临床试验申请获得国家药 品监督管理局的批准并收到《药物临床试验批准通知书》，拟开展适应症为 BC001 联合普特利单抗治疗晚期实体瘤，包括但不限于 BC001 和普特利单抗联合化疗 （XELOX，卡培他滨和奥沙利铂）一线治疗 HER-2 阴性晚期或转移性胃癌/胃食管交 界处腺癌（GC/GEJ）。现将有关信息披露如下： 一、药品基本情况 药品名称：注射用 BC001 剂型：注射剂（注射用冻干制剂） 规格：100mg/瓶 注册分类：治疗用生物制品 1 类 申请事项：境内生产药品注册临床试验 申请人：四川泸州步长生物制药有限公司 通知书编号：2023LP01707 审批结论：根据《中华人民共和国药品管理法》及有关规定， ...

证券代码：603858 证券简称：步长制药 公告编号：2023-144 山东步长制药股份有限公司 关于拟向控股子公司增资暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 2023 年 6 月 27 日，山东步长制药股份有限公司（以下简称"公司"或"步 长制药"）召开第四届董事会第四十次会议，审议通过了《关于拟增资宁波步长 医疗科技有限公司暨关联交易的议案》，同意公司控股子公司宁波步长医疗科技 有限公司（以下简称"宁波步长医疗"）全体股东（包括公司、公司关联人及其 他股东）拟按照同比例以现金方式向宁波步长医疗增资。本次增资完成后，宁波 步长医疗的注册资本将由 500 万元增加至 800 万元。具体内容详见公司 2023 年 6 月 29 日披露于上海证券交易所网站（www.sse.com.cn）的《关于拟向控股子 公司增资暨关联交易的公告》（公告编号：2023-112）。 2023 年 8 月 4 日，公司与有关各方正式签署了《关于宁波步长医疗科技有 限公司之增资协议》。具体内容详见公司 202 ...

证券代码：603858 证券简称：步长制药 公告编号：2023-142 建设单位：浙江天元生物药业有限公司 山东步长制药股份有限公司 关于控股子公司拟投资建设旧厂房提升改造项目 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 山东步长制药股份有限公司（以下简称"公司"）于 2023 年 7 月 12 日召开 了第四届董事会第四十一次会议，审议通过了《关于控股子公司浙江天元生物药 业有限公司拟投资建设旧厂房提升改造新建项目的议案》，公司控股子公司浙江 天元生物药业有限公司（以下简称"浙江天元"）为了推进其在研产品研发进展， 并考虑到未来能使产品快速进入市场做准备，拟投资建设旧厂房提升改造项目。 具体内容详见公司 2023 年 7 月 13 日 披 露 于 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）的《关于控股子公司拟投资建设旧厂房提升改造项目的公告》 （公告编号：2023-119）。 2023 年 7 月，浙江天元取得浙江省杭州市临平区经济信息化和科学技术局 签发的《浙江省 ...

Financial Performance - Revenue for the reporting period was 7.098 billion RMB, a decrease of 1.98% compared to the same period last year[15] - Net profit attributable to shareholders of the listed company was 818.38 million RMB, a decrease of 8.83% year-on-year[15] - Net cash flow from operating activities was 1.425 billion RMB, a decrease of 81.21% compared to the same period last year[15] - Total assets increased by 2.70% to 21.952 billion RMB compared to the end of the previous year[15] - The company's gross profit margin for the reporting period was 74.56%, a slight decrease of 0.34 percentage points compared to the same period last year[15] - The company's R&D expenses for the reporting period were 312 million RMB, accounting for 4.40% of total revenue[15] - The company's weighted average return on equity (ROE) increased by 0.34 percentage points to 5.52%[15] - Revenue for the first half of 2023 was RMB 69.58 billion, a decrease of 1.98% year-on-year, and net profit attributable to shareholders was RMB 7.46 billion, a decrease of 8.83% year-on-year[45] - Revenue for the reporting period was RMB 6.96 billion, a decrease of 1.98% year-over-year[48] - Operating costs decreased by 5.40% to RMB 2.18 billion compared to the same period last year[48] - Net cash flow from operating activities dropped significantly by 81.21% to RMB 267.86 million[48] - Operating revenue for the first half of 2023 was 6.96 billion RMB, slightly down from 7.10 billion RMB in the same period last year[126] - Net profit for the first half of 2023 was 683.58 million RMB, a decrease from 783.80 million RMB in the same period last year[128] - Research and development expenses were 100.30 million RMB, up from 99.55 million RMB in the previous year[126] - Interest expenses decreased to 52.55 million RMB from 72.85 million RMB in the previous year[128] - Basic earnings per share (EPS) for the first half of 2023 was 0.6746 RMB, down from 0.7399 RMB in the same period last year[128] - Total equity attributable to owners of the parent company was 10.07 billion RMB, slightly down from 10.21 billion RMB in the previous year[125] - Sales expenses increased to 3.38 billion RMB from 3.33 billion RMB in the previous year[126] - Other income decreased to 181.82 million RMB from 230.19 million RMB in the previous year[128] - R&D expenses increased to 15.89 million yuan, up 4.6% compared to the previous year[129] - Net profit reached 922.69 million yuan, a 21.6% increase year-over-year[129] - Operating cash flow decreased to 267.86 million yuan, down 81.2% from the previous year[130] - Investment cash flow turned positive at 43.01 million yuan, compared to a negative 273.58 million yuan in the previous year[131] - Financing cash flow improved to 44.17 million yuan, compared to a negative 262.55 million yuan in the previous year[131] - Cash and cash equivalents at the end of the period stood at 2.48 billion yuan, up 16.7% from the beginning of the period[131] - Sales revenue from goods and services reached 6.92 billion yuan, down 7.8% year-over-year[130] - Investment income increased to 877.77 million yuan, up 8.7% compared to the previous year[129] - Interest expenses decreased to 29.77 million yuan, down 37.0% year-over-year[129] - Total comprehensive income reached 922.72 million yuan, up 22.8% compared to the previous year[129] - Total comprehensive income for the first half of 2023 was RMB 682,987,695.35, with a decrease of RMB 593,320.80 in other comprehensive income[134] - Net profit attributable to the parent company decreased by RMB 315,662,689.31 in the first half of 2023[134] - Total owner's equity decreased by RMB 343,567,885.84 in the first half of 2023, primarily due to profit distribution of RMB 1,061,800,939.20[134] - Total comprehensive income for the first half of 2023 was RMB 775,882,426.40, with a decrease of RMB 7,922,407.86 in other comprehensive income[135] - Net profit attributable to the parent company increased by RMB 420,200,921.85 in the first half of 2023[135] - Total owner's equity increased by RMB 380,232,074.20 in the first half of 2023, despite a profit distribution of RMB 398,175,352.20[135] - Total comprehensive income for the first half of 2023 was RMB 922,716,833.92, with an increase of RMB 23,511.66 in other comprehensive income[137] - Net profit attributable to the parent company decreased by RMB 139,107,616.94 in the first half of 2023, primarily due to profit distribution of RMB 1,061,800,939.20[137] - Total owner's equity decreased by RMB 139,084,105.28 in the first half of 2023[137] - Total comprehensive income for the first half of 2023 was RMB 751,499,813.54, with a decrease of RMB 7,422,708.96 in other comprehensive income[138] Product and Market Performance - The combined revenue of the seven major products (including Brain Heart Tong Capsule, Wenxin Granule, and Danhong Injection) reached 4.461 billion RMB in the first half of 2023[18] - The combined sales revenue of the company's four exclusive products in the cardiovascular and cerebrovascular drug field reached 3.863 billion yuan in the first half of 2023[31] - The company's Brain Heart Tongue Capsule, Wenxin Granule, and Danhong Injection ranked among the top 20 in the market share of cardiovascular and cerebrovascular TCM in 2022[32] - The company's key products, including Naoxintong Capsules and Danhong Injection, generated combined revenue of RMB 4.46 billion in the first half of 2023[46] - The company's main products include Danhong Injection, Naoxintong Capsules, and Wenxin Granules[149] Research and Development - The company's R&D expenses for the reporting period were 312 million RMB, accounting for 4.40% of total revenue[15] - The company has 453 valid patents and 216 products under research, with some biological products entering Phase II or III clinical trials[33][35] - The company has 17 biological products under development, some of which have entered Phase II or III clinical trials, covering areas such as tumors, osteoporosis, anemia, and arthritis[40] - The company holds 4 vaccine products and is developing 5 additional vaccine products, including quadrivalent influenza virus split vaccines and varicella and herpes zoster vaccines[40] - The company filed 7 new patent applications and was granted 25 patents, including 19 invention patents, in the first half of 2023[47] - The company is actively developing advanced dosage forms in the chemical drug sector and focusing on generic drugs for NMPA and FDA approval[40] - The company is advancing evidence-based medical research for its leading products to enhance market reputation and drive sales growth[46] - The company is leveraging its "brain-heart co-treatment" theory to develop complementary multi-target combination therapies for cardiovascular and cerebrovascular diseases[40] - The company is strengthening its global presence by conducting research activities both domestically and internationally[40] Environmental and Social Responsibility - The company's wastewater treatment facilities discharged chemical oxygen demand (COD) at 83.8 mg/L, totaling 24.08 tons, and ammonia nitrogen at 0.873 mg/L, totaling 0.251 tons in the first half of 2023[72] - Shandong Kang'ai Pharmaceutical discharged COD at 126.5 mg/L, totaling 13.4 tons, and ammonia nitrogen at 2.05 mg/L, totaling 0.219 tons in the first half of 2023[72] - The company has six subsidiaries listed as key pollutant discharge units by environmental protection authorities, including Shandong Kang'ai Pharmaceutical and Yangling Buchang Pharmaceutical[70] - The chemical oxygen demand (COD) emission concentration at the main wastewater discharge outlet of Baoding Tianhao Pharmaceutical is 151mg/L, with a total emission of 1.9 tons in the first half of the year[74] - The ammonia nitrogen emission concentration at the main wastewater discharge outlet of Baoding Tianhao Pharmaceutical is 1.19mg/L, with a total emission of 0.015 tons in the first half of the year[74] - The nitrogen oxides emission concentration at the main wastewater discharge outlet of Baoding Tianhao Pharmaceutical is 28mg/m³, with a total emission of 0.244 tons in the first half of the year[74] - The chemical oxygen demand (COD) emission concentration at the main wastewater discharge outlet of Liaoning Aoda Pharmaceutical is 45.21mg/L, with a total emission of 3.77 tons in the first half of the year[75] - The ammonia nitrogen emission concentration at the main wastewater discharge outlet of Liaoning Aoda Pharmaceutical is 0.26mg/L, with a total emission of 0.019 tons in the first half of the year[75] - The nitrogen oxides emission concentration at the main wastewater discharge outlet of Liaoning Aoda Pharmaceutical is 28.8mg/m³, with a total emission of 0.272 tons in the first half of the year[75] - The chemical oxygen demand (COD) emission concentration at the main wastewater discharge outlet of Shandong Danhong Pharmaceutical is 83.8mg/L, with a total emission of 8.296 tons in the first half of the year[75] - The ammonia nitrogen emission concentration at the main wastewater discharge outlet of Shandong Danhong Pharmaceutical is 0.873mg/L, with a total emission of 0.086 tons in the first half of the year[75] - The chemical oxygen demand (COD) emission concentration at the main wastewater discharge outlet of Yangling Buchang Pharmaceutical is 68mg/L, with a total emission of 1.9 tons in the first half of the year[77] - The ammonia nitrogen emission concentration at the main wastewater discharge outlet of Yangling Buchang Pharmaceutical is 21.09mg/L, with a total emission of 0.59 tons in the first half of the year[77] - Shandong Buchang Pharmaceutical's GMP relocation and reconstruction project passed environmental protection acceptance (Hehuan Acceptance [2004] No. 10)[81] - Shandong Buchang Pharmaceutical's Wenxin series product production base project passed environmental protection acceptance (Hehuan Acceptance [2014] No. 0105)[81] - Shandong Buchang Pharmaceutical's drug technology R&D center construction project passed environmental protection acceptance (Hehuan Acceptance [2014] No. 23)[81] - Shandong Buchang Pharmaceutical's energy utilization project for traditional Chinese medicine residues and other waste passed environmental protection acceptance (Hehuan Acceptance [2018] No. 15)[81] - Shandong Buchang Pharmaceutical's secondary system expansion project passed environmental protection acceptance on January 14, 2023[81] - Shandong Kangai Pharmaceutical's small-volume injection and freeze-dried powder injection production project passed environmental protection acceptance (Hehuan Acceptance [2012] No. 16)[82] - Shandong Kangai Pharmaceutical's freeze-dried production line and water injection line renovation project received environmental impact report approval (Hehuan Approval [2014] No. 46)[82] - Shandong Kangai Pharmaceutical's project to produce 6 million units of injectable parecoxib sodium annually received environmental impact report approval (Hehuan Gao Report [2020] No. 27)[82] - Liaoning Aoda Pharmaceutical's project to produce 6,000 tons of new pharmaceutical excipients annually passed environmental protection acceptance (Yingbian Huan Approval [2011] No. 41)[82] - Liaoning Aoda Pharmaceutical's project to produce 10 million boxes of Mudan granules annually completed phased self-acceptance in July 2019[82] - All environmental monitoring indicators for Baoding Tianhao Pharmaceutical, Liaoning Aoda Pharmaceutical, Shandong Danhong Pharmaceutical, and Yangling Buchang Pharmaceutical were tested by qualified third-party companies and met national and local standards, with stricter controls in place to ensure compliance[88][89] - Yangling Buchang Pharmaceutical installed 114 solar photovoltaic street lamps, reducing carbon emissions by 1.8 tons[94] - Shandong Buchang Pharmaceutical's secondary system expansion project used 163 solar photovoltaic street lamps, reducing carbon emissions by 4.9 tons[94] - Liaoning Aoda Pharmaceutical's 407.16KW photovoltaic power generation project, operational since July 14, 2022, generated 331,800 kWh in the first half of 2023, reducing carbon emissions by 149.31 tons[94] - The company's subsidiaries have established comprehensive environmental management systems, maintained pollution prevention facilities, and ensured all emissions met standards[91] Corporate Governance and Shareholder Information - The company's controlling shareholder, actual controller, and other major shareholders have committed to avoiding competition with the company and its subsidiaries, with long-term effective commitments[96][97][98] - The company has established a mechanism to address unfulfilled commitments, including timely disclosure, supplementary or alternative commitments, and compensation for losses[99][100][101][102] - The company's controlling shareholder, Buchang (Hong Kong), will strictly fulfill all public commitments made during the IPO and accept social supervision[99] - The company's actual controller, Zhao Tao, will strictly fulfill all public commitments made during the IPO and accept social supervision[100] - The company's directors, supervisors, and senior management will strictly fulfill all public commitments made during the IPO and accept social supervision[101] - The company has no non-operational fund occupation by controlling shareholders or other related parties during the reporting period[103] - The company has no illegal guarantee situations during the reporting period[103] - The company has no major litigation or arbitration matters during the reporting period[105] - The company has no significant changes or handling of non-standard audit opinion matters from the previous annual report[104] - The company has no bankruptcy reorganization-related matters during the reporting period[104] - The company has no significant changes in the integrity status of the company, its controlling shareholders, or actual controllers during the reporting period[105] - The company's total number of ordinary shareholders at the end of the reporting period is 69,677[115] - The largest shareholder, Buchang (Hong Kong) Holdings Limited, holds 490,957,202 shares, representing 44.39% of the total shares[116] - The second-largest shareholder, Shoucheng International (Hong Kong) Limited, holds 82,742,400 shares, representing 7.48% of the total shares[117] - The third-largest shareholder, Hong Kong Securities Clearing Company Limited, holds 32,566,308 shares, representing 2.94% of the total shares[117] - The company's total guarantee amount for subsidiaries during the reporting period is 15,000.00 million yuan[113] - The total guarantee balance for subsidiaries at the end of the reporting period is 144,114.95 million yuan[113] - The company's total guarantee amount (A+B) is 144,114.95 million yuan, accounting for 11.96% of the company's net assets[113] - The guarantee amount for entities with a debt-to-asset ratio exceeding 70% is 121,874.95 million yuan[113] Industry and Market Trends - China's pharmaceutical manufacturing industry's total revenue in 2022 was 3,250.38 billion yuan, a year-on-year increase of 0.22%, with a significant decline in the biological drug sector[20] - The chemical drug raw material industry's revenue in 2022 was 507.71 billion yuan, a year-on-year increase of 15.00%[21] - The biological drug industry's revenue in 2022 was 397.7 billion yuan, a year-on-year decrease of 32.80%[21] - The total profit of China's pharmaceutical manufacturing industry in 2022 was 503.84 billion yuan, a year-on-year decrease of 26.73%, with the biological drug manufacturing industry's profit decreasing by 69.40%[23] - The cardiovascular and cerebrovascular disease drug market accounted for 32.28% of the clinical terminal drug market in 2022[25] - The gynecological drug market accounted for 5.77% of the urban public hospital market and 7.46% of the county-level public hospital market in 2022[27] - The top 20 gynecological drugs in the Chinese market in 2022 were led by Yimucao with a market share of 5.72%[28] - The tumor disease drug market accounted for 7.31% of the clinical terminal drug market in 2022[26] - Sales of traditional Chinese medicine (TCM) for tumor treatment have remained stable in recent years, with sales of 1,835,670 million yuan in 2022, down 6.24% from 2021[30] - The revenue of biological drugs in 2022 was 397.7 billion yuan, a year-on-year decrease of 32.80%, with a total profit of 90.43 billion yuan, down 69.40% year-on-year[30] Investments and Subsidiaries - The company invested a total of RMB 816.8 million in significant equity investments, including in Changrui Biotech (Chengdu) and Xi'an Buchang Qihang Pharmacy[53] - Changrui Biotech (Chengdu) saw a loss impact of RMB 211.22 million during the reporting period[53] - The fair value of financial assets measured at fair value decreased to RMB 1.31 billion, with trading financial assets accounting for RMB 457.63 million[55] - The company's total investment in Changrui Biotech (Chengdu) reached RMB 72 million, representing a 72% stake[54] - The company transferred 90% equity of its subsidiary, Buzhang Taoyun Health Technology (Hangzhou), to Zhao Yunhua for RMB 1, resulting in the company no longer holding any equity in the subsidiary[57] - The company's total investment in the fund "Nuoan Youxuan Return Hybrid" (证券代码:

证券代码：603858 证券简称：步长制药 公告编号：2023-139 山东步长制药股份有限公司 山东步长制药股份有限公司（以下简称"公司"）第四届监事会第二十四次 会议的通知于 2023 年 8 月 15 日发出，会议于 2023 年 8 月 25 日 9 时以通讯方式 召开，应到监事 4 人，实到 4 人，会议由监事会主席王明耿先生主持。会议的出 席人数、召开和表决方式符合《中华人民共和国公司法》等法律法规及《山东步 长制药股份有限公司章程》的相关规定，合法有效。 与会监事经认真审议，通过如下议案： 1、《关于公司 2023 年半年度报告及摘要的议案》 与会监事对 2023 年半年度报告进行了认真严格的审核，并提出了如下书面 审核意见，与会监事认为： （1）公司 2023 年半年度报告的编制和审议程序符合法律、法规、《公司章 程》及公司内部管理制度的各项规定； （2）公司 2023 年半年度报告的内容和格式符合中国证监会和上海证券交易 所的各项规定，所包含的信息能全面、真实地反映出公司 2023 年半年度报告的 经营管理和财务状况等事项； （3）未发现参与 2023 年半年度报告编制和审议的人员有违反保密 ...

证券代码：603858 证券简称：步长制药 公告编号：2023-138 山东步长制药股份有限公司（以下简称"公司"）第四届董事会第四十三次 会议的通知于 2023 年 8 月 15 日发出，会议于 2023 年 8 月 25 日 13 时以通讯方 式召开，应参会董事 15 人，实参会董事 15 人，会议由董事长赵涛先生主持。会 议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及《山 东步长制药股份有限公司章程》的相关规定，合法有效。 山东步长制药股份有限公司 第四届董事会第四十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经与会董事研究，会议审议通过了如下议案： 1、《关于公司 2023 年半年度报告及摘要的议案》 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《山 东步长制药股份有限公司 2023 年半年度报告》与《山东步长制药股份有限公司 2023 年半年度报告摘要》。 表决结果：同意 15 票，反对 0 票，弃权 0 票 独立董事对该议案发表了同意的独 ...

山东步长制药股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 根据《上海证券交易所股票上市规则》、《上海证券交易所上市公 司自律监管指引第 1 号 -- 规范运作》、《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监管要求》(2022年修订)等法 律、法规、规范性文件以及《山东步长制药股份有限公司章程》(以 下简称"《公司章程》")、《山东步长制药股份有限公司募集资金管理 制度》(以下简称"《募集资金管理制度》")等有关规定,山东步长制 药股份有限公司(以下简称"公司"或"步长制药")对 2023年半年度募 集资金存放及实际使用情况专项说明如下: 一、募集资金的基本情况 （一） 实际募集资金的金额、资金到位情况 经中国证券监督管理委员会《关于核准山东步长制药股份有限公 司首次公开发行股票的批复》(证监许可[2016]2385号)核准,本公 司向社会公开发行人民币普通股股票(A股)6,980万股(每股面值 1 元)。截至2016年11月14日止公司实际已发行人民币普通股 6,980 万股,募集资金总额为人民币 3,900,424,000.00元,扣除各项发行费 用人民币 22 ...

一、 决策程序 公司董事会已在本次董事会会议召开之前，向我们提供了《关于 公司 2023 年半年度募集资金存放与实际使用情况的专项报告的议案》 的相关资料，并进行了必要的沟通，符合《公司章程》及相关制度的 规定。 二、 独立意见 我们认为：公司 2023 年半年度募集资金存放与实际使用情况符 合中国证监会、上海证券交易所关于上市公司募集资金存放与使用的 相关规定，不存在募集资金存放和使用违规的情形。公司编制的《山 东步长制药股份有限公司 2023 年半年度募集资金存放与实际使用情 况的专项报告》内容真实、准确、完整，客观地反映了公司募集资金 存放和使用的实际情况，不存在虚假记载、误导性陈述和重大遗漏， 公司募集资金管理不存在违规情形。 （本页以下无正文） 山东步长制药股份有限公司独立董事 关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告的独立意见 根据《中华人民共和国公司法》、《中华人民共和国证券法》、中 国证监会《上市公司独立董事规则》、《山东步长制药股份有限公司章 程》（以下简称"《公司章程》"）、《山东步长制药股份有限公司独立董 事工作制度》等有关规定，我们作为山东步长制药股份有限公司 ...

证券代码：603858 证券简称：步长制药 公告编号：2023-137 山东步长制药股份有限公司 关于控股子公司药品氟康唑胶囊通过仿制药 一致性评价的公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于近日获悉，公司控股子 公司辽宁奥达制药有限公司（以下简称"辽宁奥达"）收到国家药品监督管理局 核准签发的关于氟康唑胶囊的《药品补充申请批准通知书》。该药品通过仿制药 质量和疗效一致性评价，现就相关情况公告如下： 一、药品基本情况 药品名称：氟康唑胶囊 剂型：胶囊剂 规格：50mg 注册分类：化学药品 申请内容：仿制药质量和疗效一致性评价；变更制剂处方中的辅料；变更制 剂生产工艺；变更生产批量；变更注册标准 上市许可持有人：辽宁奥达制药有限公司 营口市路南高新技术产业开发区 生产企业：辽宁奥达制药有限公司 营口市路南高新技术产业开发区 受理号：CYHB2250142 通知书编号：2023B04136 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗 器械审评审批制度的意 ...